{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-189911","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.048789+00:00","generated_at":"2026-05-31T14:19:55.044750+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Fate Therapeutics appoints Dr. Neely Mozaffarian to Board, expanding to 10 members","bullets":["Dr. Mozaffarian appointed effective July 29, 2024, as Class II director and member of NCG and Science & Technology committees.","Board increased from 9 to 10 directors; Mozaffarian fills newly created vacancy.","Received option to purchase 80,000 shares at July 29 closing price, vesting monthly over 36 months.","Mozaffarian is CMO at Atomwise with over 20 years immunology/autoimmunity R&D leadership.","Appointment adds expertise in autoimmune disease and cell therapy development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-189911","json":"https://secwatch.observer/filing/0001193125-24-189911.json","markdown":"https://secwatch.observer/filing/0001193125-24-189911.md","text":"https://secwatch.observer/filing/0001193125-24-189911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524189911/0001193125-24-189911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524189911/d764342d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:19:55.044750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3641622dcf","claim":"Neelufar Mozaffarian was appointed as Class II director at FATE THERAPEUTICS INC.","evidence_excerpt":"On July 29, 2024, the Board, following a recommendation from the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Neelufar Mozaffarian, M.D., Ph.D., FACR, to the Board, to serve as a Class II director and member of the NCG Committee and the Science and Technology Committee of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524189911/0001193125-24-189911-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}